Streamlining Rheumatology Denial Appeal Automation for Biologics

The Unique Appeal Landscape in Rheumatology

Rheumatology prior authorizations are heavily concentrated in high-cost biologics and targeted therapies, such as TNF-alpha inhibitors (e.g., Humira, Enbrel), JAK inhibitors, and other non-TNF biologics. The chronic nature of conditions like RA, PsA, and AS means ongoing PA burden and frequent re-authorization, making efficient denial management critical for sustained patient access and revenue integrity.

Common Rheumatology Denial Reasons Addressed by Automation

• Step therapy not completed, failing to document specific prior agent trial in sequence.
• Biosimilar substitution required, denying brand TNF inhibitor when a biosimilar should be tried first.
• Disease activity not documented, missing required scores like DAS28, CDAI, or PASI.
• Conservative-care duration insufficient, indicating initial conventional DMARD trial was less than payer-required duration.
• Screening documentation gaps, such as incomplete TB, hepatitis, or immunization records.
• Off-indication use without supporting payer policy for a requested biologic.

Klivira's Automated Appeal Workflow for Rheumatology

Klivira's platform automates the entire denial appeal lifecycle, starting with denial classification using normalized CARC/RARC taxonomy. For rheumatology, this means rapidly identifying specific reasons like 'step therapy not met' or 'documentation incomplete' and routing them to the correct, payer-specific appeal pathway. Our system then leverages FHIR-based data extraction to pull relevant clinical documentation from the EMR, such as disease activity scores (e.g., DAS28, SLEDAI), prior DMARD trials, and screening results, all critical for demonstrating medical necessity per ACR Treatment Guidelines.

Key Automation Capabilities for Rheumatology Appeals

• Automated appeal letter generation using per-payer templates, addressing specific denial reasons for biologics and advanced therapies.
• Clinical evidence extraction from EMRs (e.g., DAS28, PASI, TB screening results) to bolster appeal packets.
• Timely-filing window enforcement and automated status tracking to prevent lost-to-follow-up appeals.
• Outcome capture and EMR write-back, ensuring appeal results update patient records and trigger downstream billing workflows.
• Pattern feedback loop, identifying common denial reasons by payer and drug to optimize future PA submissions.

Addressing Specialty-Specific Workflow Constraints

Rheumatology presents unique challenges, including the need for periodic re-authorization of chronic-treatment biologics and the variability in biosimilar substitution policies across payers. Klivira's platform is designed to manage these complexities, offering ACR-guideline-aware policy logic, biosimilar substitution routing that handles per-payer mandates, and workflows that account for the medical-vs-pharmacy benefit split often seen with self-administered versus provider-administered biologics.

Seamless Integration with EMRs and Payer Channels

Klivira integrates with your existing EMR via SMART on FHIR, enabling efficient clinical documentation re-discovery for appeals. Submissions are routed through the payer’s preferred channel—be it X12 278, ePA, payer portals, or fax—ensuring compliance with diverse payer requirements. This connectivity minimizes manual intervention and accelerates the appeal process for critical rheumatology treatments.